Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting.
1/5 보강
[BACKGROUND] International Dermatology Outcome Measures (IDEOM) is a nonprofit organization committed to advancing the development and accessibility of evidence-based, consensus-driven outcome measure
APA
Romanelli S, Ball GD, et al. (2025). Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting.. Journal of drugs in dermatology : JDD, 24(12), 1215-1221. https://doi.org/10.36849/JDD.9232
MLA
Romanelli S, et al.. "Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting.." Journal of drugs in dermatology : JDD, vol. 24, no. 12, 2025, pp. 1215-1221.
PMID
41329147 ↗
Abstract 한글 요약
[BACKGROUND] International Dermatology Outcome Measures (IDEOM) is a nonprofit organization committed to advancing the development and accessibility of evidence-based, consensus-driven outcome measures in dermatology. This mission is supported by a diverse group of stakeholders who collaborate to improve the research and treatment of dermatologic disease.
[SUMMARY] The 2024 IDEOM Annual Meeting was held on April 5-6, 2024. During the event, work groups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed research progress and conducted breakout sessions. This report summarizes each workgroup’s updates.
[KEY MESSAGES] This report outlines the key research advancements made by each IDEOM workgroup at the 2024 IDEOM Annual Meeting.  .
[SUMMARY] The 2024 IDEOM Annual Meeting was held on April 5-6, 2024. During the event, work groups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed research progress and conducted breakout sessions. This report summarizes each workgroup’s updates.
[KEY MESSAGES] This report outlines the key research advancements made by each IDEOM workgroup at the 2024 IDEOM Annual Meeting.  .
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.